Orphazyme after FDA meeting: New phase II/III trial won't be necessary
No new phase II/III study is required pertaining to a potential US approval of the lead cnadidate arimoclomol, which is meant to treat Niemann-Pick disease type C, Chief Financial Officer at Orphazyme Anders Vadsholt tells MedWatch.
BYCHRISTOPHER DUE KARLSSON, TRANSLATED BY DANIEL PEDERSEN
It appears that Orphazyme will steer clear of the worst case scenario on the path toward US approval with its lead candidate arimoclomol, a treatment for the neurodegenerative disease, Niemann-Pick disease type C (NPC).
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Orphazyme no longer expects EMA decision this year
For subscribers
Orphazyme to discuss NPC rejection with FDA in mid-October
For subscribers
Orphazyme may face class action suit from US investors
For subscribers
